Home/ Stocks/ LPCN

Lipocine Inc.

LPCN XNAS

$2.37 -0.02 (-0.84%) ▼ 15-min delayed

Open

$2.41

High

$2.50

Low

$2.35

Volume

188.5K

Market Cap

$19.54M

About Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$119.4K	$-3,671,894	$-0.54
FY 2025	$1.98M	$-9,627,505	N/A
Q3 2025	$114.6K	$-3,186,832	$-0.59
Q2 2025	$622.8K	$-2,205,716	$-0.41

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for LPCN yet. Check out our latest market news or earnings calendar.

Get LPCN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Lipocine Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.